Levin A, Tonelli M, Bonventre J, Coresh J, Donner J-A, Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL, Jardine M et al..  2017.  Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.. Lancet. 390(10105):1888-1917.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K et al..  2016.  Complete Remission in the Nephrotic Syndrome Study Network.. Clin J Am Soc Nephrol. 11(1):81-9.

Brosius FC, Tuttle KR, Kretzler M.  2016.  JAK inhibition in the treatment of diabetic kidney disease.. Diabetologia. 59(8):1624-7.

Anderberg RJ, Meek RL, Hudkins KL, Cooney SK, Alpers CE, Leboeuf RC, Tuttle KR.  2015.  Serum amyloid A and inflammation in diabetic kidney disease and podocytes.. Lab Invest. 95(3):250-62.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PXK, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ et al..  2013.  Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.. Kidney Int. 83(4):749-56.